Correlation of Resistin with Inflammatory and Cardiometabolic Markers in Obese Adolescents with and without Metabolic Syndrome

Obesity Facts

Volumn 6, Issue 4, 2013, Pages 393-404

  Makni, Emna ^a   Moalla, Wassim ^a,b   Benezzeddine Boussaidi, Lamia ^a   Lac, Gérard ^c   Tabka, Zouhair ^a   Elloumi, Mohammed ^a,c  

^a UNIVERSITY OF SOUSSE   (Tunisia)

^b UNIVERSITY OF SFAX   (Tunisia)

^c CLERMONT AUVERGNE UNIVERSITY   (France)

Author keywords

Childhood obesity; Inflammation; Insulin resistance; Metabolic syndrome; Resistin

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; INTERLEUKIN 6; LIPID; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADOLESCENT DISEASE; ANTHROPOMETRY; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ADOLESCENT OBESITY; BODY MASS; CORRELATIONAL STUDY; DIET RESTRICTION; DISEASE ASSESSMENT; DISEASE ASSOCIATION; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; SYSTOLIC BLOOD PRESSURE;

EID: 84883153295     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000354574     Document Type: Article

References (45)

1. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome -a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
2. Zimmet P, Alberti K, George MM, et al; IDF Consensus Group: The metabolic syndrome in children and adolescents -an IDF consensus report. Pediatr Diabetes 2007; 8: 299-306.
3. Harrabi I, Bouaouina M, Maatoug J, Gaha R, Ghannem H: Prevalence of the metabolic syndrome among urban schoolchildren in Sousse, Tunisia. Int J Cardiol 2008; 135: 130-131.
4. Odrow-Sypniewska G: Markers of pro-inflammatory and pro-thrombotic state in the diagnosis of metabolic syndrome. Adv Med Sci 2007; 52: 246-250.
5. Tailor AM, Peeters PH, Norat T, Vineis P, Romaguera D: An update on the prevalence of the metabolic syndrome in children and adolescents. Int J Pediatr Obes 2010; 5: 202-213.
6. Weiss R, Dziura J, Burgert TS, et al: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374.
7. Jahagirdar R, Hemchand KP, Chiplonkar SA, Khadilkar VV, Khadilkar AV: Relationship between body mass index, fat distribution and cardiometabolic risk factors in Indian children and adolescents. Pediatr Obes 2012; 15: 7:E37-41.
8. Weiss R, Kaufman FR: Metabolic complications of childhood obesity: identifying and mitigating the risk. Diabetes Care 2008; 31(suppl 2):S310-S316.
9. Antuna-Puente B, Feve B, Fellahi S, Bastard JP: Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34: 2-11.
10. Amasyali B, Kilic A, Celik T, Iyisoy A: A new frame in thromboembolic cardiovascular disease: adipocytokine. Int J Cardiol 2010; 139: 100-102.
11. Stringer DM, Sellers EA, Burr LL, Taylor CG: Altered plasma adipokines and markers of oxidative stress suggest increased risk of cardiovascular disease in First Nation youth with obesity or type 2 diabetes mellitus. Pediatr Diabetes 2009; 10: 269-277.
12. Wassink AM, Olijhoek JK, Visseren FL: The metabolic syndrome: metabolic changes with vascular consequences. Eur J Clin Invest 2007; 37: 8-17.
13. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al: The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
14. Rea R, Donnelly R: Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 2004; 6: 163-170.
15. Hall J, Roberts R, Vora N: Energy homoeostasis: the roles of adipose tissue-derived hormones, peptide YY and ghrelin. Obes Facts 2009; 2: 117-125.
16. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455.
17. Lee JH, Chan JL, Yiannakouris N, et al: Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin resistant and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-4856.
18. Malo E, Ukkola O, Jokela M, et al: Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish health 2000 survey. Metab Syndr Relat Disord 2011; 9: 203-210.
19. Li M, Fisette A, Zhao XY, Deng JY, Mi J, Cianflone K: Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents. Int J Obes (Lond) 2009; 33: 424-439.
20. Zhang M, Zhao X, Li M, et al: Abnormal adipokines associated with various types of obesity in Chinese children and adolescents. Biomed Environ Sci 2011; 24: 12-21.
21. Holcomb IN, Kabakoff RC, Chan B, et al: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000; 19: 4046-4055.
22. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939.
23. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR: Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286-290.
24. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I: Relationship between plasma resistin concentrations, inflammatory chemokines, components of the metabolic syndrome in adults. Metabolism 2008; 57: 494-501.
25. Ferris BG: Epidemiology Standardisation Project II: recommended respiratory disease questionnaire for use with adults and children in epidemiological research. Am Rev Respir Dis 1978; 118: 7-53.
26. Rolland-Cachera MF, Cole TJ, Semp M, Tichet J, Rossignol C, Charraud A: Body mass index variations: centiles from birth to 87 years. Eur J Clin Nutr 1991; 45: 13-21.
27. Slaughter MH, Lohman TG, Boileau RA, et al: Skinfold equation for estimation of body fatness in children and youth. Hum Biol 1988; 60: 709-723.
28. Tanner JM, Whitehouse RH, Takaishi M: Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children 1965 II. Arch Dis Child 1966; 41: 613-635.
29. Wegge JK, Roberts CK, Ngo TH, Barnard RJ: Effect of diet and exercise intervention on inflammatory and adhesion molecules in postmenopausal women on hormone replacement therapy and at risk for coronary artery disease. Metabolism 2004; 53: 377-381.
30. Guzzaloni G, Grugni G, Mazzilli G, Moro D, Morabito F: Comparison between B-cell function and insulin resistance indexes in prepubertal and pubertal obese children. Metabolism 2002; 51: 1011-1016.
31. Zimmet P, Alberti G, Kaufman F, et al; International Diabetes Federation Task Force on Epidemiology and Prevention of Diabetes: The metabolic syndrome in children and adolescents. Lancet 2007; 369: 2059-2061.
32. Woo KS, Chook P, Yu CW, et al: Overweight in children is associated with arterial endothelial dysfunction and intima media thickening. Int J Obes Relat Metab Disord 2004; 28: 852-827.
33. Maffeis C, Banzato C, Talamini G; Obesity Study Group of the Italian Society of Pediatric Endocrinology and Diabetology: Waist-to-height ratio, a useful index to identify high metabolic risk in overweight children. J Pediatr 2008; 152: 207-213.
34. Lee YH, Choi SH, Lee KW, Kim DJ: ApolipoproteinB/A1 ratio is associated with free androgen index and visceral adiposity and may be an indicator of metabolic syndrome in male children and adolescents. Clin Endocrinol (Oxf) 2011; 74: 579-586.
35. Roth CL, Kratz M, Ralston MM, Reinehr T: Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children. Metabolism 2011; 60: 445-452.
36. Maggio AB, Wacker J, Montecucco F, Galan K, Pelli G, Mach F, Beghetti M, Farpour-Lambert NJ: Serum resistin and inflammatory and endothelial activation markers in obese adolescents. J Pediatr. 2012; 161: 1022-1027.
37. Suliga E: Visceral adipose tissue in children and adolescents: a review. Nutr Res Rev 2009; 22: 137-147.
38. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A: Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-5795.
39. Smith SR, Bai F, Charbonneau C, Janderov L, Argyropoulos G: A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 2003; 52: 1611-1618.
40. Cho YM, Youn BS, Chung SS, et al: Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia 2004; 47: 559-565.
41. Calabr P, Golia E, Maddaloni V, et al: Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? Intern Emerg Med 2009; 4: 25-34.
42. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S: Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010-1013.
43. Calabro P, Samudio I, Willerson JT, Yeh ET: Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335-3340.
44. Teng X, Li D, Champion HC, Johns RA: FIZZ1/RELMalpha, a novel hypoxia-induced mitogenic factor in lung with vasoconstrictive and angiogenic properties. Circ Res 2003; 92: 1065-1067.
45. Uwaifo GI, Fallon EM, Chin J, Elberg J, Parikh SJ, Yanovski JA: Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children. Diabetes Care 2002; 25: 2081-2087.